KMDA Kamada Ltd.

QT57

NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Israel

Latest market price

7.07

-0.29-4.01%

Overview Short InterestFilings

KMDAQT57Kamada Ltd.·NASDAQ

Overview Short InterestFilings

7.07-4.01%

Loading chart...

Signal & projected range

Gap down — mean-reversionHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

EOLS+1.82%$7.29 AQST+3.85%$3.92 EVO+3.29%$1.57 EBS+10.25%$7.10 IRWD+0.87%$3.49 CGC+6.87%$0.73 TLRY+5.49%$2.69 COLL+0.17%$23.72

Snapshot

Index	—	P/E	19.37	EPS (ttm)	0.38	Insider Own	3.17%	Shs Outstand	57.69M	Perf Week	-7.30%

Market Cap	424.63M	Forward P/E	12.76	EPS next Y	0.58	Insider Trans	-10.93%	Shs Float	31.66M	Perf Month	-11.43%

Enterprise Value	364.63M	PEG	1.04	EPS next Q	0.13			Short Float	0.62%	Perf Quarter	0.27%

Income	22.00M	P/S	2.21	EPS this Y	29.93%			Short Ratio	1.61	Perf Half Y	-11.22%

Sales	192.00M	P/B	1.57	EPS next Y	20.77%	ROA	5.81%	Short Interest	197.49K	Perf YTD	4.25%

Book/sh	4.68	P/C	6.07	EPS next 5Y	18.61%	ROE	8.37%	52W High	9.35 -24.44%	Perf Year	7.92%

Cash/sh	1.21	P/FCF	15.73	EPS past 3/5Y	— -2.03%	ROIC	6.90%	52W Low	6.55 7.86%	Perf 3Y	75.66%

Dividend Est.	0.17 (2.41%)	EV/EBITDA	8.89	Sales past 3/5Y	11.74% 6.24%	Gross Margin	40.82%	Volatility	3.65% 2.65%	Perf 5Y	30.27%

Dividend TTM	0.42 (5.94%)	EV/Sales	1.90	EPS Y/Y TTM	11.47%	Oper. Margin	14.51%	ATR (14)	0.26	Perf 10Y	32.14%

Dividend Ex-Date	Aug 27, 2026	Quick Ratio	2.29	Sales Y/Y TTM	12.94%	Profit Margin	11.60%	RSI (14)	36.17	Recom	2.17

Dividend Gr. 3/5Y	—	Current Ratio	4.06	EPS Q/Q	23.08%	SMA20	-5.83%	Beta	0.92	Target Price	15.00

Payout	63.73%	Debt/Eq	0.04	Sales Q/Q	22.22%	SMA50	-10.00%	Rel Volume	1.31	Prev Close	7.36

Employees	462	LT Debt/Eq	0.04	Earnings	Nov 09	SMA200	-8.21%	Avg Volume	128.94K	Price	7.07

IPO Date	May 31, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	42.22% 8.03%	Net Debt/EBITDA	-1.46	Volume	168,896	Change	-4.01%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Sep-18-26	Reiterated	UBS		$15
Jul-21-26	Reiterated	William Blair		$15
Mar-11-26	Reiterated	Stifel Nicolaus		$20 → $11
Dec-09-25	Reiterated	HC Wainwright & Co.	Buy	$13
Nov-13-24	Reiterated	Stifel Nicolaus		$20

Latest News· Times ET

Nov-02-26

Nov-02-2607:00AM

Kamada to Announce Third Quarter and Nine Months Ended September 30, 2026, Financial Results on November 9, 2026Yahoo

Oct-19-26

Oct-19-2607:00AM

Kamada Announces Participation in the Stifel 2026 Healthcare Conference and the Jefferies Global Healthcare Conference in London During November 2026globenewswire.com

Oct-06-26

Oct-06-2607:00AM

Kamada Announces Expansion of Biosimilars Portfolio with the Launch of Two Additional Products in Israelglobenewswire.com

Sep-29-26

Sep-29-2607:01AM

Director At Kamada Acquires Company Stock Options Worth $162KBenzinga

Sep-28-26

Sep-28-2605:03AM

Kamada Targets $205M Revenue as Plasma Therapies, Kedrab Demand Fuel Growthdefenseworld.net

Sep-23-26

Sep-23-2607:00AM

David Tsur Executes Major Move: Acquires $61K In Kamada Stock OptionsBenzinga

Sep-17-26

Sep-17-2607:00AM

CDC Highlights Significant Increase in U.S. Rabies Exposures and Anti-Rabies Immunoglobulin Utilization; Kamada Confirms Sufficient KedRAB® Supply to Meet Increased Demandglobenewswire.com

Sep-10-26

Sep-10-2607:00AM

Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conferenceglobenewswire.com

Sep-08-26

Sep-08-2607:02AM

Director At Kamada Exercises Options Worth $77KBenzinga

Sep-03-26

Sep-03-2604:01PM

Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholdersglobenewswire.com

Sep-01-26

Sep-01-2601:00AM

AI Exhaustion? 3 Healthcare Stocks With 38% EPS Growth That Could Be The CureSeekingAlpha

Aug-17-26

Aug-17-2607:00AM

Kamada Declares Cash Dividend of $0.17 Per Share; The Company Reported Record-High Revenue and Profitability for First Six Months of 2026globenewswire.com

Aug-14-26

Aug-14-2601:45PM

Is Kamada (KMDA) a Solid Growth Stock? 3 Reasons to Think "Yes"zacks.com

12:41PM

KMDA or PRTA: Which Is the Better Value Stock Right Now?zacks.com

10:56AM

Wall Street Analysts Think Kamada (KMDA) Could Surge 79.06%: Read This Before Placing a Betzacks.com

Company

Kamada Ltd. is a biopharmaceutical firm focused on developing, manufacturing, and distributing protein therapeutics derived from human plasma. The company operates through two core business areas: its proprietary product segment and its distribution division. Its own manufactured portfolio includes KAMRAB/KEDRAB for rabies prevention, CYTOGAM to prevent cytomegalovirus disease in transplant recipients, WINRHO SDF for immune thrombocytopenic purpura and Rhesus (Rh) isoimmunization, HEPAGAM B for hepatitis B recurrence prevention following liver transplants and for post-exposure prophylaxis, VARIZIG for post-exposure chickenpox prophylaxis, and GLASSIA for intravenous alpha-1 antitrypsin deficiency (AATD). Kamada also produces KamRho (D) for the prophylaxis of hemolytic disease of newborns and immune thrombocytopenic purpura, along with a specific antiserum for Vipera palaestinae and Echis coloratus snake bites. Additionally, the company distributes a wide array of third-party pharmaceutical products, encompassing treatments like BRAMITOB for chronic pulmonary infections, FOSTER for asthma, PROVOCHOLINE for diagnosing bronchial airway hyperactivity, and specialized therapies such as IVIG for immunodeficiency, VARITECT for chickenpox and zoster herpes, and various factors for hemophilia A and B, among numerous others for conditions like hepatitis B, cytomegalovirus, angioedema, Japanese encephalitis, and prostate cancer. Kamada markets its offerings in the United States through strategic partners and internationally via a network of distributors. The company maintains significant collaborations with Takeda Pharmaceuticals Company Limited, PARI GmbH, and Kedrion Biopharma. Established in 1990, Kamada Ltd. is headquartered in Rehovot, Israel.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	192	180	161	143	—	—	—	—	—
Cost of Goods Sold Incl. D&A	113	104	91	87	—	—	—	—	—
Gross Profit	78	76	70	55	—	—	—	—	—
Selling, General and Administrative Excl. Other	37	34	31	27	—	—	—	—	—
Research and Development	10	13	15	14	—	—	—	—	—
Other Operating Expense	3	3	4	4	—	—	—	—	—
Operating Income	29	26	20	10	—	—	—	—	—
Interest Expense	0	1	1	1	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	0	-2	-6	0	—	—	—	—	—
Net Income Before Taxes	26	23	13	8	—	—	—	—	—
Income Taxes	4	3	-1	0	—	—	—	—	—
Consolidated Net Income	22	20	14	8	—	—	—	—	—
Net Income From Continuing Operations	22	20	14	8	—	—	—	—	—
Net Income	22	20	14	8	—	—	—	—	—
EPS (Recurring)	0.38	0.38	0.25	0.17	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	0.38	0.38	0.25	0.17	—	—	—	—	—
EPS (Diluted)	0.38	0.37	0.25	0.15	—	—	—	—	—
EBITDA	41	39	28	22	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	18.59	19.08	24.36	40.80	—	—	—	—	—
Price To Sales Ratio	2.13	2.27	2.16	2.10	—	—	—	—	—
Gross Margin	40.63	42.22	43.48	38.46	—	—	—	—	—
Operating Margin	15.10	14.44	12.42	6.99	—	—	—	—	—
Net Margin	11.46	11.11	8.70	5.59	—	—	—	—	—
Shares Outstanding	58	58	57	49	—	—	—	—	—
Market Capitalization	410	409	347	300	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Brenner Yael	VP Quality	Sep 14 '26	Option Exercise	5.93	16,964	100,597	12,766	Sep 17
Livneh Nir	VP, General Counsel	Sep 14 '26	Option Exercise	5.37	10,000	53,700	10,000	Sep 17
Tsur David	Director	Sep 14 '26	Sale	8.18	22,827	186,725	407,929	Sep 17
Tsur David	Director	Sep 09 '26	Sale	8.26	175	1,446	430,756	Sep 11
Tsur David	Director	Sep 08 '26	Sale	8.26	162,760	1,344,398	430,931	Sep 11
Tsur David	Director	Sep 07 '26	Sale	8.28	14,238	117,891	593,691	Sep 11
Tsur David	Director	Sep 02 '26	Option Exercise	6.71	49,000	328,690	634,429	Sep 08
Brenner Yael	VP Quality	Sep 02 '26	Option Exercise	5.94	3,036	18,034	9,302	Sep 08
Brenner Yael	VP Quality	Aug 26 '26	Option Exercise	6.25	10,000	62,500	16,266	Aug 31

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.